GSK and Boehringer Ingelheim prevailed in the first U.S. Zantac cancer case to go to trial, according to Bloomberg.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK Pharma call volume above normal and directionally bullish
- GSK announces SWIFT-1, SWIFT-2 trials on depemokimab met primary endpoints
- GSK facing whistleblower lawsuit from lab related to Zantac, Bloomberg says
- GSK says FDA approves Benlysta Autoinjector for children with SLE
- GSK to Divest Final Shares in Haleon
